TransMedics Group remains a Strong Buy, driven by robust revenue growth, expanding organ platforms, and strategic international initiatives. Learn more about TMDX stock here.
Zacks Investment Research on MSN
Reasons to retain TransMedics stock in your portfolio for now
TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (“OCS”) technology. The optimism, led by solid third-quarter 2025 results, ...
TransMedics Group's Organ Care System (OCS) is transforming organ transplantation. The company should be well-positioned to dominate the organ transplant market for decades. TransMedics believes it ...
TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.
We came across a bullish thesis on TransMedics Group, Inc. on Johnny’s bearish Investing’s Substack. In this article, we will ...
Nasdaq 100 composition highlights TransMedics (NASDAQ:TMDX) and its advanced organ preservation and transport systems.
TransMedics' stock is overvalued despite recent revenue growth, with a 25% annual growth rate priced in, while the transplant market grows at 8.5% CAGR. The company faces stiff competition from ...
Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results